CRISPR Therapeutics

CRSP

Market cap $5.1B

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.

It may be the spawn of a company that faded into irrelevancy, but GE Vernova is thriving as a standalone outfit. Most investors may not appreciate just how long it takes CRISPR Therapeutics to complete a dosing regimen and start collecting revenue.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.

Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also could deliver a win for investors.

Subscribers to  Chart of the Week  received this commentary on Sunday, November 16.

CRISPR Therapeutics' sole approved product doesn't generate much sales yet. It does have some pipeline candidates that could make progress over the next year.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad approvals, revenue growth is gradual due to complex treatment logistics and patient adoption hurdles. CRSP's pipeline includes promising in-vivo cardiovascular, CAR-T oncology/autoimmune, and diabetes programs, with key updates expected in 2025.

Ark Investment sold 395,617 shares worth about $25 million. It represents a minor change in its 13F assets under management (AUM).